BeOne MedicinesONC -2.29%79 Net Debt Paydown Yield % is -0.02% as of Jul. 09, 2026. GuruFocus rates ONC with a GF Score™ of 79/100 and a GF Value™ of $357.86 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,157 Biotechnology companies, BeOne Medicines ranks worse than 54.02% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, BeOne Medicines's Net Debt Paydown Yield % was -0.02%.
BeOne Medicines (NAS:ONC) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
BeOne Medicines Net Debt Paydown Yield % Related Terms
BeOne Medicines Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ONC vs MRNA, RPRX, ROIV: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, BeOne Medicines's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of -0.02% mean?
BeOne Medicines (ONC) has a Net Debt Paydown Yield % of -0.02% as of Jul. 09, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #625 out of 1157 companies in the Biotechnology industry, placing it in the top 54%.
Is BeOne Medicines' Net Debt Paydown Yield % too high?
BeOne Medicines' current Net Debt Paydown Yield % is -0.02%. Based on the distribution chart, BeOne Medicines ranks #625 out of 1157 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BeOne Medicines has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Net Debt Paydown Yield % compare to MRNA and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #625 out of 1157 companies for Net Debt Paydown Yield %. This places BeOne Medicines in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Net Debt Paydown Yield % is -0.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $357.86, compared to a current price of $301.88 — trading 15.6% below its estimated fair value. The current Net Debt Paydown Yield % is -0.02%. BeOne Medicines' overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Net Debt Paydown Yield % is -0.02% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $301.88 is trading 15.6% below its estimated GF Value™ of $357.86.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
Net Debt Paydown Yield %: -0.02%
GF Value™: $357.86 vs. price of $301.88 (15.6% below fair value)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
79GF Score
Get the complete analysis for ONC
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
